H-IV . com - HIV and AIDS news and articles
Home Site Map

Home HIV Testing Kits

About HIV and Home HIV Testing Kits
With HIV testing, there is an unofficial stigma attached with the process, which often prevents many people from being tested However as much as we decide to avoid the Human Immunodeficiency Virus (HIV), HIV has the potential to pose as a major threat to life

A Fragile Lifeline: Lessons I Learned Answering The Aids Hotline
Dial 1-800/AIDSNYCEvery Monday and Wednesday morning, promptly at 10 a.m.

Failure to Act by the Kentucky House of Representatives Leaves Hundreds of Kentucky HIV/AIDS Patients with an Uncertain Future
No Funding for Kentucky AIDS Drug Assistance Program in Proposed Commonwealth Budget; Lead by Kentucky Equality Federation, 12 other Kentucky Organizations want the Kentucky AIDS Drug Assistance Program Restored

FDA Approves First Diagnostic Assay to Detect Both HIV Antigen and Antibodies
Test advances ability to detect HIV infection earlier SILVER SPRING, Md., June 21 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved the first assay to detect both antigen and antibodies to Human Immunodeficiency Virus (HIV).

Welcome to H-IV .com - For HIV and AIDS news and information

Featured video - "Did I Just Contract HIV? Symptoms of Primary HIV Infection"

Dr Becky Kuhn from AIDSvideos.org presents "Did I Just Contract HIV? Symptoms of Primary HIV Infection". From the description, "It's sometimes possible to recognize when you've recently contracted HIV from signs and symptoms such as fever, rash, or swollen lymph nodes. This video will teach you how to recognize signs and symptoms of primary HIV infection that are experienced by between 40 and 90% of individuals after they are first infected with HIV. Primary HIV infection occurs during the first few weeks or months after a person first becomes infected with HIV."

Latest HIV News -

Loading...

 

Abbott to Feature Novel Tests and New Upgrades to Testing Platforms at American Association for Clinical Chemistry Lab Expo
ANAHEIM, Calif., July 26 /PRNewswire-FirstCall/ -- A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott (NYSE: ABT) will highlight at this year's American Association for Clinical Chemistry Lab Expo (AACC) which starts today in Anaheim.

New Research Reveals MTV, UNICEF and PEPFAR's Ignite Campaign has Altered Young People's Thinking About HIV/AIDS Attitudes and Behaviours
VIENNA, July 20 /PRNewswire/ -- INTERNATIONAL AIDS CONFERENCE 2010 -- MTV, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and UNICEF today unveiled at INTERNATIONAL AIDS CONFERENCE 2010, new research on its Staying Alive Ignite Campaign at, which found that creating compelling pro-social entertainment for young people can positively impact attitudes and behaviour towards HIV and AIDS. MTV, with funding from the Bill & Melinda Gates Foundation, commissioned Johns Hopkins University to evaluate the Project Ignite HIV prevention and education campaign, MTV Staying Alive's TV drama series Shuga, Africa's hard-hitting drama for young people with compelling HIV prevention and education messages.

Report Warns Flat Global Funding for HIV Prevention Research May Limit Ability of Researchers to Move Promising Approaches Forward
VIENNA, July 20 /PRNewswire-USNewswire/ -- Following significant advances in vaccine and microbicide research, including results presented today of 39% efficacy in the CAPRISA 004 microbicide gel trial among women in South Africa, a new report released today warns that flat funding for HIV prevention research may limit researchers' ability to quickly move promising approaches forward.

Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
VIENNA, July 19 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients.

Scientists, HIV Advocates Call for Better Methods to Evaluate the Increased Risk of Cardiovascular Disease in Persons with HIV
Two-Fold Increase in Risk May Be Directly Linked to HIV WASHINGTON, July 19 /PRNewswire-USNewswire/ -- At the same time that medical science has nearly eliminated AIDS deaths in patients treated for human immunodeficiency virus (HIV), two international meetings of HIV/AIDS scientists and patient advocates find major shortcomings in the design and analysis of studies used to assess cardiovascular disease (CVD) risk in people with HIV with significant implications for improving medical care.

International Organizations Agree to Take Concerted Action to End Pediatric HIV/AIDS
"No child should enter this world infected with HIV." VIENNA, Austria, July 19 /PRNewswire-USNewswire/ -- A global alliance of international organizations, including the heads of UNICEF, UNAIDS and The Global Fund to Fight AIDS, Tuberculosis and Malaria as well as other NGOs including the Pan African Treatment Access Movement, Health GAP, Ugandan Pediatric Association and the Global AIDS Alliance today agreed to take concerted action to eliminate pediatric HIV/AIDS over the next five years, preventing nearly 400,000 children annually from beginning their lives infected with the virus that causes AIDS. "Every day, almost 1,000 babies are infected with HIV – and without diagnosis and treatment, half of these babies will not live to see th...

Pelosi: Obama Administration's National HIV/AIDS Strategy Is First Comprehensive Plan to Reduce Impact of HIV/AIDS
WASHINGTON, July 13 /PRNewswire-USNewswire/ -- Speaker Nancy Pelosi issued the following statement applauding the Obama Administration's release of the National HIV/AIDS Strategy: "The National HIV/AIDS Strategy represents the nation's first comprehensive plan to reduce the impact of HIV/AIDS in this country.




Privacy Policy | Copyright/Trademark Notification